Overview

PsA Treatment With hOKT3γ1 (Ala-Ala)

Status:
Terminated

Trial end date:
2008-06-25

Target enrollment:

Participant gender:

Summary

hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are unable to control their arthritis with methotrexate or azathioprine.

Phase:

Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator:

Immune Tolerance Network (ITN)

Treatments:

Muromonab-CD3